Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 28

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 1
Chunk 28
---
  
    Paid-in  
    Subscription  
    Accumulated  

    Shares  
    Amount  
    Shares  
    Amount  
    Capital  
    Receivable  
    Deficit  
    Total 
  
    PBAX Closing Equity as of February 13, 2024 
     -  
    $-  
     2,741  
    $-  
    $547  
    $-  
    $(12,709,426) 
    $(12,708,879)
  
    Forfeiture of founders shares 
     -  
     -  
     (438) 
     -  
     -  
     -  
     -  
     - 
  
    Adjusted shares outstanding 
     -  
     -  
     2,303  
     -  
     547  
     -  
     (12,709,426) 
     (12,708,879)
  
    Shares issued as consideration in the Merger 
     -  
     -  
     4,038  
     1  
     47,238,749  
     -  
     -  
     47,238,750 
  
    Loss on VIE consolidation 
     -  
     -  
     -  
     -  
     -  
     -  
     (4,836,216) 
     (4,836,216)
  
    Expense IPR&D 
     -  
     -  
     -  
     -  
     -  
     -  
     (45,640,000) 
     (45,640,000)
  
    Reclassification of public shares 
     -  
     -  
     41  
     -  
     911,358  
     -  
     -  
     911,358 
  
    Issuance of common stock as payment to vendors 
     -  
     -  
     825  
     -  
     3,182,550  
     -  
     -  
     3,182,550 
  
    Elimination of deferred